May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Long Term Experience With the Express Miniature Glaucoma Device Under a Scleral Flap
Author Affiliations & Notes
  • M. R. Ben-Hur
    Clinical Affairs, Optonol Ltd, Neve Ilan, Israel
  • E. Dahan
    Ophthalmology, University of Witwatersrand, Johannesburg, South Africa
  • Footnotes
    Commercial Relationships  M.R. Ben-Hur, Optonol Ltd, E; E. Dahan, Optonol Ltd, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4180. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. R. Ben-Hur, E. Dahan; Long Term Experience With the Express Miniature Glaucoma Device Under a Scleral Flap. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4180. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the long term safety and efficacy of the ExPRESS device implantation under a scleral flap in glaucoma patients.

Methods: : Non-randomized prospective study. Outcome measures included intra-ocular pressure, number of anti-glaucoma medications, complications and success rate with a follow-up period of four years.

Results: : Ninety-seven eyes of 72 patients with open-angle glaucoma (OAG) were implanted under a scleral flap with the ExPRESS miniature glaucoma device. Thirty-three eyes (34%) had the surgery combined with cataract extraction and intra-ocular lens implantation. Thirty-eight eyes (39%) had received previous glaucoma surgery. There were 52 Caucasians, 17 Africans, 19 Indians, 2 Asians and 7 of Mixed and unknown race in the group. Mean IOP (±SD) dropped from 29.9 mmHg ±8.8 (n=96) preoperatively to 14.4 ± 2.9 mmHg (n=59), 14.4 ± 3.5 (n=34), and 14.6 ± 3.1 (n=12 ) at 2, 3, and 4 years, respectively. The drop in IOP was significant between baseline and all time points (t-test, p=0.000). Mean number of medications dropped significantly from 2.72 ± 1.26 mmHg preoperatively to 0.68 ± 0.25, 0.33 ± 0.48, and 0.31 ± 0.63 at 2, 3, and 4 years respectively (p=0.01 after 4 years). Twelve eyes required surgery for procedure-related problems (5 AC release, 3 device exchanges, 3 flap revisions, and 1 cataract extraction).Qualified success (IOP≤18 mmHg with or without anti-glaucoma medications) were 90%, 83.3% and 73.3% at 2, 3 and 4 years, respectively.

Conclusions: : Implanting the Ex-PRESS miniature glaucoma device under a scleral flap resulted in good IOP control, with significant reduced anti-glaucoma medication and high success rate after 4 years of follow-up

Keywords: intraocular pressure • neuroprotection • wound healing 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.